Borderline Resectable and Locally Advanced Pancreas Cancer


The AJR Lecture Series brings presentations on the most important AJR articles to your desktop, available for viewing at home or office and on your schedule. This Lecture has an estimated time to complete the activity of 1 hour.


Target Audience:
The target audience for this activity is radiologists at all training levels with an interest in pancreatic imaging.

Goals and Objectives:
After completing the material in this article, the learner should be able to:
  1. Discuss how metabolic metrics from PET/MRI can assess pathologic response to NAT as well as predict survival; and
  2. Articulate how the widely used serum biomarker CA 19-9, either in terms of the baseline value or in terms of normalization after NAT, is not associated with pathologic response or survival.


Disclosure of Commercial Interest:
  • H. Jacene receives research support from Siemens Healthcare and GTx, Inc. Dr. Jacene receives speaking and teaching honoraria from Janssen Pharmaceuticals and is a member of the advisory board and receives consulting fees from Advanced Accelerator Applications.
  • A. Goenka has nothing to disclose.
  • M. Truty has nothing to disclose.
  • C. Neumann has nothing to disclose.


Member Price:
Free
NonMember Price:
$250.00

Accreditation Statement
The American Roentgen Ray Society (ARRS) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.

Designation Statement
The ARRS designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The American Medical Association has determined that physicians not licensed in the US who participate in this CME activity are eligible for AMA PRA Category 1 Credit(s)™.

Date of issuance: July 23, 2021
Date of expiration: 7/22/2024
Estimated time to complete the activity: 1 hour(s)